? Mutant Mouse/Viral Vector Core The objective of this Core is to provide expert advice from the talented team of co-investigators, necessary training, and the infrastructure to utilize molecular biological approaches to create genetically engineered mouse models that will increase the depth and breadth of existing drug abuse research and stimulate new research at Virginia Commonwealth University and throughout the scientific community. Additionally, it will provide a mechanism for scientists both within and outside of the drug abuse field to interact to develop new research projects. Specifically, this Core will provide investigators the necessary training, tools, and expertise to: 1) create novel genetically modified mice, not currently available through other sources; 2) maintain mice in a repository in which available mouse lines will be bred, genotyped, and transferred to the investigator upon weaning; 3) cryogenically preserve mouse lines for use in future studies; 4) develop viral- vectors to over-express, knock-down or deliver dominant negative forms of study genes chosen by collaborating investigators; and 5) deliver viral vectors stereotaxically into specific brain regions of interest and verify the extent of the manipulation. Overall, this Core will provide new services to multiple investigators, with the goals of providing state-of-the-art molecular biological tools to investigate drugs of abuse, facilitate collaborations, and provide value to drug abuse researchers.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
2P30DA033934-06
Application #
9572671
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
2024-03-31
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Donvito, Giulia; Nass, Sara R; Wilkerson, Jenny L et al. (2018) The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology 43:52-79
Wolstenholme, Jennifer T; Bowers, M Scott; Pais, Alexander B et al. (2018) Dietary Omega-3 Fatty Acids Differentially Impact Acute Ethanol-Responsive Behaviors and Ethanol Consumption in DBA/2J Versus C57BL/6J Mice. Alcohol Clin Exp Res :
Hermes, Douglas J; Xu, Changqing; Poklis, Justin L et al. (2018) Neuroprotective effects of fatty acid amide hydrolase catabolic enzyme inhibition in a HIV-1 Tat model of neuroAIDS. Neuropharmacology 141:55-65
Mischel, Ryan A; Dewey, William L; Akbarali, Hamid I (2018) Tolerance to Morphine-Induced Inhibition of TTX-R Sodium Channels in Dorsal Root Ganglia Neurons Is Modulated by Gut-Derived Mediators. iScience 2:193-209
Shin, Myungsun; Snyder, Helena W; Donvito, Giulia et al. (2018) Liposomal Delivery of Diacylglycerol Lipase-Beta Inhibitors to Macrophages Dramatically Enhances Selectivity and Efficacy in Vivo. Mol Pharm 15:721-728
Gonek, Maciej; McLane, Virginia D; Stevens, David L et al. (2018) CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward. Brain Behav Immun 69:124-138
Curry, Zachary A; Wilkerson, Jenny L; Bagdas, Deniz et al. (2018) Monoacylglycerol Lipase Inhibitors Reverse Paclitaxel-Induced Nociceptive Behavior and Proinflammatory Markers in a Mouse Model of Chemotherapy-Induced Neuropathy. J Pharmacol Exp Ther 366:169-183
Cooper, Ziva D; Poklis, Justin L; Liu, Fei (2018) Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073. Neuropharmacology 134:92-100
Akbarali, Hamid I; Dewey, William L (2017) The gut-brain interaction in opioid tolerance. Curr Opin Pharmacol 37:126-130
Dempsey, Sara K; Poklis, Justin L; Sweat, Kacie et al. (2017) Acute Toxicity From Intravenous Use of the Tricyclic Antidepressant Tianeptine. J Anal Toxicol 41:547-550

Showing the most recent 10 out of 93 publications